- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01019603
A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris
June 22, 2017 updated by: Stiefel, a GSK Company
A Single-Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris
The purpose of this study is to assess systemic exposure of a new foam formulation of tazarotene, 0.1% compared with Tazorac Gel, 0.1%.
The study design and dosing regimen are based on previous clinical studies with Tazorac Gel and Tazorac Cream.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
A single-center, randomized, open-label, phase 1, comparative bioavailability study in subjects with moderate to severe acne vulgaris.
Approximately 30 subjects will be enrolled and randomized to 1 of the 2 study product groups in a 1:1 ratio (tazarotene foam: Tazorac Gel).
Study product will be applied once daily for 22 days to the face, upper chest, upper back, and shoulders.
Following the baseline visit, subjects will return to the study center daily for study product application.
Blood samples to determine plasma concentrations of tazarotenic acid will be collected before study product application on days 1, 8, 12, 15, 18, 20, and 22, and collected at multiple time points over a 72 hour period on days 22 through 25.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Austin, Texas, United States, 78759
- Dermresearch, Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years and older (ADULT, OLDER_ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female 12 years of age or older who is in good general health.
- Have an Investigator's Static Global Assessment (ISGA) score of 3 or greater at baseline. The area considered for the ISGA must be confined to the face.
- Regular menstrual cycle prior to study entry (as reported by the subject) for females of childbearing potential.
- Negative urine pregnancy test for females of childbearing potential. • Sexually active females of childbearing potential participating in the study must agree to use a medically acceptable method of contraception while receiving protocol-assigned product. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant; including perimenopausal women who are less than 2 years from their last menses.
Women who are not currently sexually active must agree to use medically accepted methods of contraception should they become sexually active while participating in the study. Male subjects and/or their partners must use a medically acceptable form of contraception.
- Nonsmoker or smoker with at least 30 days abstinence from smoking or using nicotine-containing products prior to study entry and willing not to smoke or to use nicotine-containing products throughout the study.
- Ability and willingness to follow all study procedures, attend all scheduled visits, and successfully complete the study.
- Capable of understanding and willing to provide signed and dated written voluntary informed consent before any protocol specific procedures are performed
Exclusion Criteria:
- Female who is pregnant, trying to become pregnant, or breast feeding.
- History of known or suspected intolerance to any of the ingredients of the study products.
- Use of topical antibiotics or topical corticosteroids for acne treatment within the past 2 weeks.
- Use of systemic corticosteroids within the past 4 weeks.
- Use of systemic retinoids (eg, isotretinoin) within the past 6 months.
- Concurrent use of medications known to be photosensitizers because of the possibility of augmented photosensitivity.
- Use of topical anti-acne medications (eg, benzoyl peroxide, retinoids) within the past 2 weeks.
- Concomitant use of of facial products such as: abradants, facials, peels containing glycolic or other acids .
- Facial procedure (eg, chemical or laser peel or microdermabrasion) performed by an esthetician, beautician, physician, nurse, or other practitioner within the past 2 weeks.
- History or evidence of skin conditions other than acne (eg, eczema) that would interfere with the subject's participation in the study.
- Consumption of alcohol within 24 hours prior to study product application on days 8, 12, 15, 18, 20, and 22 and within 72 hours post application on day 22.
- Consumption of xanthine-containing beverages or products (eg, caffeinated coffee, tea, over-the counter medication for cold symptoms) within 24 hours prior to study product application on days 8, 12, 15, 18, 20, and 22 and within 72 hours post-application on day 22.
- Anticipated need to engage in activities or exercise that would cause profuse sweating during the study.
- Anticipated need for surgery or hospitalization during the study.
- Require or desire excessive or prolonged exposure to ultraviolet light (eg, sunlight or tanning beds) during the study.
- Concurrent involvement in another investigational study or participation within 30 days prior to the start of this study.
- Any other condition that, in the judgment of the investigator, would put the subject at unacceptable risk for participation in the study.
- Currently lives in the same household as currently enrolled subjects; is an employee of Stiefel, an investigator, or a contract research organization involved in the study; or is an immediate family member (eg, partner, offspring, parents) of an employee involved in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1
Tazarotene foam 0.1%
|
Topical Tazarotene foam applied daily for 22 days.
Other Names:
|
ACTIVE_COMPARATOR: 2
Tazaroc Gel 0.1%
|
Topical tazarotene gel applied daily for 22 days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Plasma concentrations of tazarotenic acid in subjects with acne vulgaris
Time Frame: Days 1, 8, 12, 15, 18, 20, 22 (pre-dose and 3, 4.5, 6, 7.5, 9, 12, 16, 20, 24, 38, 48, 62, and 72 hr post-dose
|
Days 1, 8, 12, 15, 18, 20, 22 (pre-dose and 3, 4.5, 6, 7.5, 9, 12, 16, 20, 24, 38, 48, 62, and 72 hr post-dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 12, 2009
Primary Completion (ACTUAL)
December 20, 2009
Study Completion (ACTUAL)
December 20, 2009
Study Registration Dates
First Submitted
November 19, 2009
First Submitted That Met QC Criteria
November 23, 2009
First Posted (ESTIMATE)
November 25, 2009
Study Record Updates
Last Update Posted (ACTUAL)
June 23, 2017
Last Update Submitted That Met QC Criteria
June 22, 2017
Last Verified
June 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 114565
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Study Data/Documents
-
Statistical Analysis Plan
Information identifier: 114565Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Informed Consent Form
Information identifier: 114565Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Study Protocol
Information identifier: 114565Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Clinical Study Report
Information identifier: 114565Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Dataset Specification
Information identifier: 114565Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Individual Participant Data Set
Information identifier: 114565Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Annotated Case Report Form
Information identifier: 114565Information comments: For additional information about this study please refer to the GSK Clinical Study Register
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acne Vulgaris
-
Galderma R&DCompletedSevere Acne VulgarisUnited States, Canada, Puerto Rico
-
Sebacia, Inc.CompletedInflammatory Acne VulgarisUnited States
-
Nexgen Dermatologics, Inc.Unknown
-
Rejuva Medical AestheticsHealMD, LLCNot yet recruitingAcne Vulgaris (Disorder)United States
-
InMode MD Ltd.Active, not recruitingInflammatory Acne VulgarisUnited States
-
PollogenLumenis Be Ltd.RecruitingModerate to Severe Acne VulgarisUnited States
-
Boston PharmaceuticalsCompletedModerate to Severe Acne VulgarisUnited States, Canada
-
Bispebjerg HospitalCompleted
-
Actavis Mid-Atlantic LLCCompletedMILD TO SEVERE ACNE VULGARISIndia
-
Assiut UniversityCompleted
Clinical Trials on Tazarotene
-
UCSF Benioff Children's Hospital OaklandNational Cancer Institute (NCI)CompletedNeoplastic SyndromeUnited States
-
Stiefel, a GSK CompanyGlaxoSmithKlineCompletedAcne VulgarisUnited States, Canada
-
Stiefel, a GSK CompanyGlaxoSmithKlineCompletedAcne VulgarisUnited States, Canada
-
UCSF Benioff Children's Hospital OaklandNational Cancer Institute (NCI)Completed
-
Stiefel, a GSK CompanyGlaxoSmithKlineCompleted
-
GRI Bio Operations, Inc.RecruitingIdiopathic Pulmonary FibrosisUnited States
-
Postgraduate Institute of Medical Education and...CompletedAtrophic Post Acne ScarringIndia
-
Stiefel, a GSK CompanyGlaxoSmithKlineCompletedAcne VulgarisUnited States
-
Stewart, Roger H., M.D., P.A.CompletedACTINIC KERATOSESUnited States
-
Dana-Farber Cancer InstituteBayerTerminatedSolid Tumor | Hand-Foot Skin Reaction (HFSR)United States